Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
